Bicycle Therapeutics (BCYC) vs Fate Therapeutics (FATE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 41.1% versus a loss of 53.9%. Over five years, BCYC leads with a -93.6% price change compared with -96.5% for FATE. Bicycle Therapeutics is the larger company by market cap ($270.1 million vs $262.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | FATE |
|---|---|---|
| Share price | $3.86 | $2.19 |
| Market cap | $270.10M | $262.41M |
| 1-day change | +1.29% | +2.82% |
| YTD return | -46.19% | +117.35% |
| 1-year return | -53.87% | +41.06% |
| 5-year return | -93.57% | -96.52% |
| EPS (TTM) | $-2.73 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $3.23 |
| 52-week low | $3.33 | $0.95 |
| Distance from 52-week high | -57.59% | -32.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +146.18% | +162.10% |
| Average volume | 387.29K | 1.86M |
| Shares outstanding | 50.55M | 119.82M |
| Employees | 288 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed BCYC by 94.9 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
BCYC vs FATE FAQ
Which is bigger, Bicycle Therapeutics or Fate Therapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $270.10M compared with $262.41M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, BCYC or FATE?
FATE returned +41.06% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Fate Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bicycle Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Fate Therapeutics.